These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7928205)

  • 1. Optimization of a negative oral contrast agent for magnetic resonance imaging.
    Davis MA; Mei H; Ritsema GH
    Invest Radiol; 1994 Jun; 29 Suppl 2():S120-2. PubMed ID: 7928205
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of AMI-227 as an oral contrast agent for magnetic resonance imaging.
    Rogers J; Lewis J; Josephson L
    Invest Radiol; 1994 Jun; 29 Suppl 2():S81-2. PubMed ID: 7928278
    [No Abstract]   [Full Text] [Related]  

  • 3. A potentially artifact-free oral contrast agent for gastrointestinal MRI.
    Liebig T; Stoupis C; Ros PR; Ballinger JR; Briggs RW
    Magn Reson Med; 1993 Nov; 30(5):646-9. PubMed ID: 8259066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
    Oksendal AN; Jacobsen TF; Gundersen HG; Rinck PA; Rummeny E
    Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of AMI-227 as an oral MR contrast agent.
    Rogers J; Lewis J; Josephson L
    Magn Reson Imaging; 1994; 12(4):631-9. PubMed ID: 8057768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low density barium and bentonite mixture versus high density barium: a comparative study to optimize negative gastrointestinal contrast agents for MRI.
    Paley MR; Nicolas AI; Mergo PJ; Torres GM; Burton SS; Ros PR
    Magn Reson Imaging; 1997; 15(9):1033-6. PubMed ID: 9364949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Splenosis: value of MRI with injection of a superparamagnetic contrast agent].
    Roussel A; Petit E; Mallet L; Zins M
    J Radiol; 2008 Dec; 89(12):1944-6. PubMed ID: 19106854
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative studies on the efficacy of MRI contrast agents in MRA.
    Weinmann HJ; Bauer H; Ebert W; Frenzel T; Radüchel B; Platzek J; Schmitt-Willich H
    Acad Radiol; 2002 May; 9 Suppl 1():S135-6. PubMed ID: 12019849
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase III trial of oral magnetic particles in MRI of abdomen and pelvis.
    MacVicar D; Jacobsen TF; Guy R; Husband JE
    Clin Radiol; 1993 Mar; 47(3):183-8. PubMed ID: 8472481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of an oral magnetic particle formulation as a gastrointestinal contrast agent for magnetic resonance imaging.
    Rubin DL; Muller HH; Young SW; Hunke WA; Gorman WG
    Invest Radiol; 1994 Jan; 29(1):81-6. PubMed ID: 8144343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR cholangiopancreatography diagnosis of juxtapapillary duodenal diverticulum simulating a cystic lesion of the pancreas: usefulness of an oral negative contrast agent.
    Mazziotti S; Costa C; Ascenti G; Gaeta M; Pandolfo A; Blandino A
    AJR Am J Roentgenol; 2005 Aug; 185(2):432-5. PubMed ID: 16037516
    [No Abstract]   [Full Text] [Related]  

  • 12. Biodistribution and toxicity of MR imaging contrast media.
    Oksendal AN; Hals PA
    J Magn Reson Imaging; 1993; 3(1):157-65. PubMed ID: 8428083
    [No Abstract]   [Full Text] [Related]  

  • 13. Ferrimagnetic susceptibility contrast agents.
    Bach-Gansmo T
    Acta Radiol Suppl; 1993; 387():1-30. PubMed ID: 8390776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-enhanced magnetic resonance angiography in the coronary and peripheral arteries.
    Saeed M; Wendland MF; Engelbrecht M; Sakuma H; Higgins CB
    Acad Radiol; 1998 Apr; 5 Suppl 1():S108-12. PubMed ID: 9561057
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of peritoneal tolerance of a new MR blood pool contrast agent in rabbits.
    Hilfiker PR; Debatin JF; Tarlo K; Schmitz HC; Kurrer MO
    Invest Radiol; 1999 Nov; 34(11):722-7. PubMed ID: 10548385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of MR colonography.
    Achiam MP; Chabanova E; Løgager V; Thomsen HS; Rosenberg J
    Abdom Imaging; 2007; 32(4):457-62. PubMed ID: 17019654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo animal tests of an artifact-free contrast agent for gastrointestinal MRI.
    Briggs RW; Wu Z; Mladinich CR; Stoupis C; Gauger J; Liebig T; Ros PR; Ballinger JR; Kubilis P
    Magn Reson Imaging; 1997; 15(5):559-66. PubMed ID: 9254000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.
    Grubnic S; Padhani AR; Revell PB; Husband JE
    AJR Am J Roentgenol; 1999 Jul; 173(1):173-8. PubMed ID: 10397122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visualization of superior mesenteric lymph nodes by the combined oral and intravenous administration of the ultrasmall superparamagnetic iron oxide, AMI-227.
    Rogers JM; Lewis J; Josephson L
    Magn Reson Imaging; 1994; 12(8):1161-5. PubMed ID: 7854022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.